prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype Basal, SPECIMENS: A. SENTINEL LYMPH NODE LEFT AXILLA. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. C. WIDE LOCAL EXCISION LEFT BREAST. DIAGNOSIS: A. SENTINEL LYMPH NODE #1, LEFT AXILLA: -ONE LYMPH NODE, NO TUMOR SEEN (0/1). B. SENTINEL LYMPH NODE #2, LEFT AXILLA: -ONE LYMPH NODE, NO TUMOR SEEN (0/1). C. WIDE LOCAL EXCISION, LEFT BREAST: -INVASIVE AND IN-SITU DUCTAL CARCINOMA, SBR GRADE III/III WITH. EXTENSIVE NECROSIS AND CANCERIZATION OF LOBULES, SEE TEMPLATE. Invasive Breast Cancer Template. INVASIVE TUMOR: Histologic type: ductal. Tumor Size (cm): 2.5 cm. Size of Invasive Focus: 2.5 cm. Grade, Histologic: 3. Grade, Nuclear: 3. Mitoses. 3. Scarff Bloom Richardson grade: III. Necrosis: present. Invasion Vasc/Lymphatic: absent. DCIS component. DCIS Quantity: <25%. DCIS Type: Clining. DCIS Location: outside main mass: diffuse. Nuclear grade: high. Necrosis: absent. Margins: DCIS present within 1 hpf of lateral and 1 mm of deep and medial margins. Lymph nodes: Negative (0/2). Stage, Pathology : T2N1. Hormone receptor status (by IHC): ER & PR: PENDING. HERCEPTEST (by IHC): Pending. ADDENDUM. The ER/PR/HER2 status of the invasive breast carcinoma was determined by immunohistochemistry. and quantitated via ACIS (image analysis). Results are as follows: ER. 0%. PR. 0%. HER2. 2.3 (borderline). A separate ACIS report has been generated. NOTE: FISH analysis for HER2 gene amplification has been ordered. Addendum. Fluorescence in situ hybridization (FISH) for Her-2 gene amplification. Her-2/neu gene: Not amplified. Ratio of Her-2/neu to CEP17: 1.21. The assay is performed on formalin fixed, paraffin embedded section using Her-2 DNA probe kit from. Vysis. The quality of the fluorescence signals and tissue section is adequate for analysis. The signals of. both Her-2 and CEP17 are counted in 60 invasive tumor nuclei. The Her-2 gene is considered amplified. when the ratio of Her-2 to CEP17 signal is >2.0. SPECIMEN(S): A. SENTINEL LYMPH NODE LEFT AXILLA B. SENTINEL LYMPH NODE #2 LEFT AXILLA C. WIDE. LOCAL EXCISION LEFT BREAST. CLINICAL HISTORY: None. FROZEN SECTION DIAGNOSIS: A. SENTINEL LYMPH NODE LEFT AXILLA. Touch prep: No tumor seen by Dr. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. Touch prep: No tumor seen by Dr. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE LEFT AXILLA. Received fresh is a 1x0.8x0.5cm. lymph node. It is bisected and touch prep done. Specimen entirely. submitted for permanent section. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received fresh is sentinel lymph node left axilla measuring 0.7x0.5x0.4cm. It is bisected and touch prep. done. Submitted in toto in cassette B for permanent section. C. WIDE LOCAL EXCISION LEFT BREAST. Received fresh is an oriented portion of breast tissue measuring 6x5.5x2.7cm Sectioning shows a well. circumscribed tan nodular tumor mass measuring 2.5x1.8x1cm. It closely approaches the superior. posterior medial margin. Specimen is inked as follows: superior red, inferior orange, medial green,. lateral yellow, posterior black. Tumor tissue and normal tissue given for tissue procurement and tumor. sent for flow cytometry. Representative sections submitted in seventeen cassettes. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist. Final: Pathologist. Addendum: Pathologist. Addendum Review: Pathologist. Addendum Final: Pathologist. Addendum: Pathologist, 1. Addendum Review: Pathologist,. Addendum Final: Pathologis.

expanded version (tokens=1409) : 
 Histological classification: 
- Invasive ductal carcinoma with a subtype of Basal 
- In-Situ ductal carcinoma. 

Description of any Necrosis: 
- Extensive necrosis identified within the invasive carcinoma. 
- Absence of necrosis in DCIS component.

Tumor infiltrating lymphocytes: 
- No mention of lymphocytes infiltrating the tumor.

Histological grade: 
- SBR histologic grade III/III. 
- Nuclear grade 3. 
- Scarff Bloom Richardson grade III. 

Lymphovascular invasion: 
- No evidence of lymphovascular invasion.

Calcification: 
- No mention of calcification identified.

Receptor status: 
- ER and PR receptor status pending. 
- HER2 receptor status was initially borderline (IHC 2.3), but FISH analysis later showed not amplified.

IHC and any other ancillary testing results: 
- ACIS report was generated to quantify ER, PR, and HER2 receptor status through immunohistochemistry. 
- HER2 FISH analysis showed the Her2/neu gene was not amplified (ratio of 1.21).
- Touch prep frozen sections were negative for both sentinel lymph nodes extracted.
- Tissue procurement and tumor analysis was done using flow cytometry.

Other important details: 
- The tumor size was 2.5 cm. 
- There was no involvement of lymph nodes (0/2).
- Pathological staging is T2N

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1577) : 
 The report states Invasive Ductal Carcinoma, with a Basal subtype,  SBR Grade III/III, Nuclear Grade 3, and Scarff Bloom Richardson Grade III. As per the pathology report on sentinel lymph node biopsies, no metastasis was found. HER2 gene was not amplified by FISH and ER/PR is pending. The tumor size is 2.5 cm without evidence of lymphovascular invasion or calcification. Tissue procurement and tumor analysis were done using flow cytometry; Touch prep frozen sections were negative for both sentinel lymph nodes extracted.

